Today, one of the most promising methods of combating COVID-19 is considered complete vaccination, which should provide collective immunity to more than 65% of the total population. As you know, the World Health Organization (WHO) has approved the accelerated registration procedure for vaccines against SARSCoV-2, and several vaccines are already available for use in a number of countries. Table 1 provides a summary of comparative data on various vaccines and their effectiveness when used.

Population, comparative data on various vaccines, complete vaccination

Abbasi J. COVID-19 and mRNA Vaccines-First Large Test for a New Approach. JAMA. 2020 Sep 3. PubMed: https://pubmed.gov/32880613. Full-text: https://doi.org/10.1001/jama.2020.16866

Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P; PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020 Oct 22;371:m3939. PubMed: https://pubmed.gov/33093056. Full-text: https://doi.org/10.1136/bmj.m3939

Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016 Sep;12(9):2351-6. PubMed: https://pubmed.gov/27269431. Full-text: https://doi.org/10.1080/21645515.2016.1177688

Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KWR, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2020, published 27 October. Full-text: https://doi.org/10.1016/S1473-3099(20)30773-8

Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. PubMed: https://pubmed.gov/32142651. Full-text: https://doi.org/10.1016/j.cell.2020.02.052

WHO 20200409. WHO target product profiles for COVID-19 vaccines. WHO 2020, published 9 April, accessed 2 September, 2020. Full-text: https://www.who.int/who-documents-detail/who-target-product-profiles-for-covid-19-vaccines

WHO 20200506. Key criteria for the ethical acceptability of COVID-19 human challenge studies. WHO 2020, published 6 May. Full-text: https://www.who.int/ethics/publications/key-criteria-ethical-acceptability-of-covid-19-human-challenge/en/

WHO 20201231. WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access. WHO 2020, published 31 December. Full-text: https://www.who.int/news/item/31-12-2020-who-issues-its-first-emergency-use-validation-for-a-covid-19-vaccine-and-emphasizes-need-for-equitable-global-access